Abstract | OBJECTIVE: PATIENTS AND METHODS: RESULTS: After 4 months follow-up, a 0.7 (1.0)% HbA1c reduction was found, accompanied by a -2.8 (11.5) UI/day TDI decrease. Weight dropped for 73.7% of patients, with an average -2.0 (2.7) kg reduction. A global cHDL increase was noted after treatment, while no differences were observed for total cholesterol, triglycerides or cLDL. SBP dropped significantly, but no change in DBP was observed. CONCLUSION:
|
Authors | Pedro Pujante, Jessica Ares, Carmen Maciá, Raúl Rodriguez Escobedo, Edelmiro Menéndez, Elías Delgado |
Journal | Medicina clinica
(Med Clin (Barc))
Vol. 152
Issue 11
Pg. 438-441
(06 07 2019)
ISSN: 1578-8989 [Electronic] Spain |
PMID | 30503071
(Publication Type: Journal Article, Multicenter Study, Observational Study)
|
Copyright | Published by Elsevier España, S.L.U. |
Chemical References |
- Benzhydryl Compounds
- Blood Glucose
- Cholesterol, HDL
- Glucosides
- Glycated Hemoglobin A
- Insulin
- Sodium-Glucose Transporter 2 Inhibitors
- hemoglobin A1c protein, human
- Canagliflozin
- dapagliflozin
- empagliflozin
|
Topics |
- Adult
- Aged
- Benzhydryl Compounds
(administration & dosage)
- Blood Glucose
(drug effects)
- Blood Pressure
(drug effects)
- Body Weight
(drug effects)
- Canagliflozin
(administration & dosage)
- Cholesterol, HDL
(drug effects)
- Diabetes Mellitus, Type 2
(drug therapy)
- Female
- Glucosides
(administration & dosage)
- Glycated Hemoglobin
(drug effects)
- Humans
- Insulin
(analysis, therapeutic use)
- Male
- Middle Aged
- Retrospective Studies
- Sodium-Glucose Transporter 2 Inhibitors
(administration & dosage)
- Weight Loss
(drug effects)
|